MR Fingerprinting: A Novel Sequence Applied to Neuroimaging

Sponsor
University of North Carolina, Chapel Hill (Other)
Overall Status
Completed
CT.gov ID
NCT03800537
Collaborator
(none)
14
1
1
41.4
0.3

Study Details

Study Description

Brief Summary

Magnetic Resonance Imaging (MRI) has become one of most important medical imaging tools over the past 30 years because it is non-invasive, requires no ionizing radiation, and provides exquisite images of soft tissues and anatomic structures with many tissue/disease specific contrasts. While MRI has served the community well for many years, it is increasingly clear that it also has significant limitations.

One of the principle limitations is the lack of quantitative information for tissue/structure characterization. The current paradigm of MRI is to use a set of scanner settings to generate an image "weighted" by a specific MR contrast mechanism (physical parameter), where it is hoped that variations in the parameter will be accentuated. However, without quantitative knowledge of the parameters, the final image contrast may depend on many factors, which complicates image interpretation and diagnostic performance. Quantitative measurement can provide a great deal of information about tissue properties and pathological conditions, since these parameters ultimately determine the contrast that is observed in conventional images.

Condition or Disease Intervention/Treatment Phase
  • Device: MR Fingerprinting
N/A

Detailed Description

The purpose of this study is to evaluate novel quantitative MRI techniques in clinical studies to determine whether they can provide better, faster and more useful information for clinical diagnosis. Quantitative MRI has been a continuous interest in the MRI community, but extremely challenging due to long acquisition times and sensitivity to motion. Recently, the investigators have introduced a novel MRI data acquisition approach, namely MR Fingerprinting (MRF), for simultaneous measurement of several important parameters in a single MRI scan.

In this study, the investigators propose to apply MR Fingerprinting at UNC and evaluate its performance for different neurological diseases. The investigators hypothesize that the quantitative MR imaging technique will lead to improved tissue characterization and diagnosis.

Study Design

Study Type:
Interventional
Actual Enrollment :
14 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
MR Fingerprinting: A Novel Sequence Applied to Neuroimaging
Actual Study Start Date :
Mar 8, 2019
Actual Primary Completion Date :
Aug 18, 2022
Actual Study Completion Date :
Aug 18, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: All Participants

All participants will receive the investigational MR Fingerprinting sequence.

Device: MR Fingerprinting
The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.

Outcome Measures

Primary Outcome Measures

  1. Percent of Patients with Visible Region of Interest (Imaging Visibility) [Immediately following MRI completion, within approximately 5 minutes]

    MR fingerprinting sequences will be examined to determine their utility for visualizing pathology.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • The study will include English-speaking patients that are already scheduled to undergo a clinical neurological MRI for diagnostic purposes.
Exclusion Criteria:
  • Pregnant women will be excluded.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of North Carolina at Chapel Hill Chapel Hill North Carolina United States 27599

Sponsors and Collaborators

  • University of North Carolina, Chapel Hill

Investigators

  • Principal Investigator: Yueh Z Lee, MD, PhD, University of North Carolina, Chapel Hill

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
NCT03800537
Other Study ID Numbers:
  • 18-2071
First Posted:
Jan 11, 2019
Last Update Posted:
Aug 23, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 23, 2022